Real-world Survival Outcomes in Patients with Locally Advanced or Metastatic NTRK Fusion-Positive Solid Tumors Receiving Standard-of-care Therapies Other Than Targeted TRK Inhibitors.
PLoS ONE（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined